BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32754549)

  • 1. Down syndrome presenting with different hematological manifestations: A case series of four cases.
    Shangpliang D; Dey B; Das J; Baishya P; Raphael V; Khonglah Y
    J Family Med Prim Care; 2020 May; 9(5):2569-2572. PubMed ID: 32754549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down syndrome with different hematological manifestations: a short series of 3 cases with review of literature.
    Manivannan P; Prasaad PR; Kar R; Basu D
    Indian J Hematol Blood Transfus; 2013 Mar; 29(1):31-4. PubMed ID: 24426330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematological disorders in children with Down syndrome.
    Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
    Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinctive hematological abnormalities in East Asian neonates and children with Down syndrome.
    Kim DW; Kim HR; Shin MG; Baek HJ; Kook H; Hwang TJ; Shin JH; Suh SP; Ryang DW
    Int J Lab Hematol; 2011 Aug; 33(4):369-77. PubMed ID: 21692995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRAME immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome.
    Chisholm KM; Rivetta CV; Heerema-McKenney A
    Ann Clin Lab Sci; 2015; 45(2):121-7. PubMed ID: 25887863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
    Langebrake C; Creutzig U; Reinhardt D
    Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
    Watanabe K
    Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing therapy for myeloid disorders of Down syndrome.
    Webb DK
    Br J Haematol; 2005 Oct; 131(1):3-7. PubMed ID: 16173956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.
    Boztug H; Schumich A; Pötschger U; Mühlegger N; Kolenova A; Reinhardt K; Dworzak M
    Cytometry B Clin Cytom; 2013; 84(6):370-8. PubMed ID: 23450818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid Leukemia of Down Syndrome.
    Kosmidou A; Tragiannidis A; Gavriilaki E
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.
    Roy A; Roberts I; Vyas P
    Semin Fetal Neonatal Med; 2012 Aug; 17(4):196-201. PubMed ID: 22421527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA1 mutations in acute leukemia in children with Down syndrome.
    Magalhães IQ; Splendore A; Emerenciano M; Figueiredo A; Ferrari I; Pombo-de-Oliveira MS
    Cancer Genet Cytogenet; 2006 Apr; 166(2):112-6. PubMed ID: 16631466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina.
    Pennella CL; Cassina TM; Rossi JG; Baialardo EM; Rubio P; Deu MA; Peruzzo L; Guitter MR; Sanchez de La Rosa CG; Alfaro EM; Felice MS
    Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid Proliferations Associated with Down Syndrome: Clinicopathologic Characteristics of Forty Cases from Five Large Academic Institutions.
    van den Akker TA; Liu YC; Liu H; Chapman J; Levine JM; Weinberg OK; Geyer JT
    Pathobiology; 2024; 91(1):89-98. PubMed ID: 36996802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Mechanisms of the Genetic Predisposition to Acute Megakaryoblastic Leukemia in Infants With Down Syndrome.
    Grimm J; Heckl D; Klusmann JH
    Front Oncol; 2021; 11():636633. PubMed ID: 33777792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myeloid proliferations related to Down syndrome].
    Hasegawa D
    Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down's Syndrome-Transient Abnormal Myelopoiesis and Acute Leukaemia.
    Bain B
    Leuk Lymphoma; 1991; 3(5-6):309-17. PubMed ID: 27467421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of myeloid leukemia in children with Down syndrome.
    Saida S
    Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
    Brink DS
    Adv Anat Pathol; 2006 Sep; 13(5):256-62. PubMed ID: 16998319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study.
    Brouwer N; Matarraz S; Nierkens S; Hofmans M; Nováková M; da Costa ES; Fernandez P; Bras AE; de Mello FV; Mejstrikova E; Philippé J; Grigore GE; Pedreira CE; van Dongen JJM; Orfao A; van der Velden VHJ; On Behalf Of The EuroFlow Consortium
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.